Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025)
Legend Biotech (LEGN) reported Non-Current Deffered Revenue of -$277000.0 for Q2 2025, up 5.46% on a YoY basis from -$262657.0 in Q2 2024, and down 106.72% quarter-over-quarter from -$134000.0 in Q1 2025.
Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Legend Biotech has reported Non-Current Deffered Revenue for 7 years, with the latest figure at -$277000.0 in Q2 2025.
- For the quarter ending Q2 2025, Non-Current Deffered Revenue rose 5.46% year-over-year to -$277000.0; the trailing twelve-month figure through Jun 2025 stood at -$277000.0 (up 5.46% YoY), and the FY2023 full-year result was $48.0 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q2 2025 stood at -$277000.0, down from -$134000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $48.0 million in Q4 2023, with the low at -$484000.0 in Q3 2023.
- Historically, Non-Current Deffered Revenue has averaged $2.8 million across 5 years, with a median of -$188000.0 in 2021.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue sank 158.77% — and 2024, when it climbed 18.61%.
- Legend Biotech's Non-Current Deffered Revenue stood at -$295000.0 in 2021, then advanced by 20.68% to -$234000.0 in 2022, then surged by 20596.58% to $48.0 million in 2023, then slumped by 100.9% to -$430000.0 in 2024, then surged by 35.58% to -$277000.0 in 2025.
- The last three Non-Current Deffered Revenue figures came in at -$277000.0 (Q2 2025), -$134000.0 (Q1 2025), and -$430000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 225.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -277,000.00 |
| Mar 31, 2025 | -134,000.00 |
| Sep 30, 2024 | -430,000.00 |
| Jun 30, 2024 | -293,000.00 |
| Mar 31, 2024 | -157,000.00 |
| Dec 31, 2023 | 47.96 Mn |
| Sep 30, 2023 | -484,000.00 |
| Jun 30, 2023 | -360,000.00 |
| Mar 31, 2023 | -131,000.00 |
| Sep 30, 2022 | -234,000.00 |
| Jun 30, 2022 | -156,000.00 |
| Mar 31, 2022 | -77,000.00 |
| Dec 31, 2021 | -295,000.00 |
| Sep 30, 2021 | -219,000.00 |
| Jun 30, 2021 | -144,000.00 |
| Mar 31, 2021 | -71,000.00 |
| Dec 31, 2020 | -114,000.00 |
| Dec 31, 2019 | 277.77 Mn |